Vivos Therapeutics Inc. (VVOS)

NASDAQ: VVOS · Real-Time Price · USD

2.69

-0.15 (-5.28%)

At close: May 01, 2025, 2:29 PM

-5.28% (1D)

Bid	2.69
Market Cap	15.84M
Revenue (ttm)	15.03M
Net Income (ttm)	0
EPS (ttm)	-2.22
PE Ratio (ttm)	-1.21
Forward PE	n/a
Analyst	Buy

Ask	2.74
Volume	69,282
Avg. Volume (20D)	117,837
Open	2.78
Previous Close	2.84
Day's Range	2.69 - 2.75
52-Week Range	1.91 - 6.28
Beta	7.28

About VVOS

Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers the Vivos System, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. Vivos Therapeutics also offers VivoScore Program, a screening ...

[Read more]

Industry Medical - Devices

Sector Healthcare

IPO Date Dec 11, 2020

Employees 109

Stock Exchange NASDAQ

Ticker Symbol VVOS

Website https://vivos.com

Full Company Profile

Analyst Forecast

According to 2 analyst ratings, the average rating for VVOS stock is "Buy." The 12-month stock price forecast is $6.1, which is an increase of 126.77% from the latest price.

Stock Forecasts

Next Earnings Release

Vivos Therapeutics Inc. is scheduled to release its earnings on May 13, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

2 months ago

+10.9%

Vivos Therapeutics shares are trading higher after... Unlock content with Pro Subscription

7 months ago

-22.03%

Vivos Therapeutics shares are trading lower after the company announced a $4.3 million registered offering of 1.36 million shares of common stock at $3.15 per share.

News

1 month ago · seekingalpha.com

Vivos Therapeutics, Inc. (VVOS) Q4 2024 Earnings Call Transcript

Vivos Therapeutics, Inc. (NASDAQ:VVOS ) Q4 2024 Earnings Conference Call March 31, 2025 5:00 PM ET Company Participants Bradford Amman - CFO, Treasurer & Secretary Kirk Huntsman - Co-Founder, Chairman...

1 month ago · zacks.com

Vivos Therapeutics, Inc. (VVOS) Reports Q4 Loss, Lags Revenue Estimates

Vivos Therapeutics, Inc. (VVOS) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $3.05 per share a year ago.

2 months ago · proactiveinvestors.com

Vivos Therapeutics sees strong adoption of OSA treatment, expands strategic alliance

Vivos Therapeutics (NASDAQ:VVOS) announced an expansion of its strategic marketing and distribution alliance with Rebis Health into two additional locations in Colorado. The company said initial data ...